OncoFOLLOW - Personalized Liquid Biopsy for Patient Monitoring
OncoFOLLOW: The first personalised liquid biopsy in the market. Monitor the progression and detect lack of response. OncoFOLLOW is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears. This assay is customised for each patient, as it analyses up to 15 variants previously identified in the tumour of the patient. In addition, it sequences a fixed panel of 40 genes associated with response/resistance to targeted therapies and immunotherapy, and/or frequently mutated in cancer. In 2013, OncoDNA became the first company to launch a personalized liquid biopsy test.
SAMPLE TYPE: Liquid biopsy
RECOMMENDED FOR:
All stage IV solid tumours in adults that have been previously sequenced (with OncoDEED or any other test sequencing more than 100 genes).
GENES PANEL:
- 40 genes
- Up to 15 variants previously identified in the tumour
MATERIAL: 2 blood samples (2x10ml Streck tubes)
PERSONALIZED TOOL
The gene panel is customised for each patient by selecting a set of patient-specific variants, which were identified in the tumour by a previous sequencing test (with OncoDEEP, or with any other test sequencing more than 100 genes)
A MINIMALLY INVASIVE TECHNIQUE
From a simple blood sample, this minimally invasive technique allows to follow the treatment response very closely and identify new targets if the cancer becomes resistant to the current therapy, and it may detect relapse earlier than routine imaging technologies.